These tumors are driven by SS18:SSX fusion oncogenes generated from the chromosomal translocation of the SS18 gene which codes for a subunit of the BAF chromatin remodeling complex (SWI/SNF complex) with the transcriptional repressors SSX1, SSX2, or SSX4 (synovial sarcoma, X breakpoint genes) which ultimately disrupts global chromatin remodeling and has noted downstream effects on key oncogenic signaling pathways involving E-cadherin, Bcl-2, Mcl1, and Wnt [6, 7]. This evidence concerns the gene SSX2 and synovial sarcoma.